Structures of 70 unique G protein-coupled receptors (GPCRs) have been determined, with
over 370 structures in total bound to different ligands and the receptors in various …

ABSTRACT Introduction: Adenosine A2A Receptor (A2AR) antagonists are an emerging
class of agents that treat cancers, both as a monotherapy and in combination with other …

Purpose: To evaluate AZD4635, an adenosine A2A receptor antagonist, as monotherapy or
in combination with durvalumab in patients with advanced solid tumors. Patients and …

Purpose: There are several agents in early clinical trials targeting components of the
adenosine pathway including A2AR and CD73. The identification of cancers with a …

The computational prediction of relative binding free energies is a crucial goal for drug
discovery, and G protein-coupled receptors (GPCRs) are arguably the most important drug …

Background Adenosine is a potent immunosuppressant whose levels in the tumor
microenvironment (TME) are often much higher than those in normal tissues. Binding of …

Adenosine receptors (ARs) are transmembrane proteins that belong to the G protein-
coupled receptors (GPCRs) superfamily and mediate the biological functions of adenosine …

Background Adenosine receptor type 2 (A2AR) inhibitor, AZD4635, has been shown to
reduce immunosuppressive adenosine effects within the tumor microenvironment (TME) and …

Increased risks of peripheral toxicity and undesired adverse effects associated with
chemotherapeutic agents are the major medical hurdles in cancer treatment that worsen the …

Conventional animal models in oncology consist of immunodeficient mice injected with
human‐derived tumor cells. Whilst such human xenograft models have been invaluable in …